Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on Safety and Efficacy of Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT03485118 is registered in ClinicalTrials.gov with Zhejiang Hisun Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT03485118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03485118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on Safety and Efficacy of Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 12, 2016
Completion date
January 14, 2018
Enrollment
137 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma